Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRVS Corvus Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CRVS
Price (delayed)
$4.43
Market cap
$341.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$337.77M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells
Highlights
Corvus Pharmaceuticals's equity has surged by 51% QoQ and by 48% YoY
The quick ratio has grown by 45% YoY
Corvus Pharmaceuticals's net income has shrunk by 67% YoY but it has increased by 34% QoQ
The EPS has increased by 39% QoQ but it has decreased by 22% YoY
The debt has grown by 11% YoY and by 2.8% from the previous quarter
Key stats
What are the main financial stats of CRVS
Market
Valuations
Earnings
Shares outstanding
77.11M
Market cap
$341.62M
Enterprise value
$337.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.21M
Net income
-$41.4M
EBIT
-$41.4M
EBITDA
-$41.32M
Free cash flow
-$28.56M
Per share
Balance sheet
Liquidity
EPS
-$0.62
EPS diluted
-$0.96
Free cash flow per share
-$0.4
Book value per share
$0.72
Revenue per share
$0
TBVPS
$0.82
Total assets
$59.44M
Total liabilities
$10.11M
Debt
$1.15M
Equity
$49.33M
Working capital
$36.21M
Debt to equity
0.02
Current ratio
4.9
Quick ratio
4.77
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65.8%
Return on equity
-113.8%
Return on invested capital
-141.1%
Return on capital employed
-82.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVS stock price
How has the Corvus Pharmaceuticals stock price performed over time
Intraday
32.24%
1 week
22.38%
1 month
50.68%
1 year
118.23%
YTD
-17.2%
QTD
39.31%
Financial performance
How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.21M
Net income
-$41.4M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has shrunk by 67% YoY but it has increased by 34% QoQ
The operating income has declined by 35% year-on-year and by 13% since the previous quarter
Price vs fundamentals
How does CRVS's price correlate with its fundamentals
Growth
What is Corvus Pharmaceuticals's growth rate over time
Valuation
What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 39% QoQ but it has decreased by 22% YoY
The price to book (P/B) is 85% higher than the 5-year quarterly average of 3.3 but 44% lower than the last 4 quarters average of 10.9
Corvus Pharmaceuticals's equity has surged by 51% QoQ and by 48% YoY
Efficiency
How efficient is Corvus Pharmaceuticals business performance
The ROE has dropped by 90% year-on-year but it is up by 41% since the previous quarter
Corvus Pharmaceuticals's return on invested capital has shrunk by 77% YoY but it has increased by 44% QoQ
The company's return on assets rose by 39% QoQ but it fell by 30% YoY
Dividends
What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVS.
Financial health
How did Corvus Pharmaceuticals financials performed over time
Corvus Pharmaceuticals's total liabilities has shrunk by 72% QoQ but it has surged by 50% YoY
The total assets has grown by 48% YoY but it has contracted by 14% from the previous quarter
The debt is 98% less than the equity
Corvus Pharmaceuticals's equity has surged by 51% QoQ and by 48% YoY
The debt to equity has declined by 33% since the previous quarter and by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.